

# BPH GLOBAL LIMITED

ACN 009 104 330

31 October 2024

Company Announcements Platform  
Australian Securities Exchange

## Quarterly activities report

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”), a plant-based biotechnology company, today released its Appendix 4C and Quarterly Activities Report for the period ended 30 September 2024.

During the September Quarter, the Company continued to engage deeply with prospective investors with a particular focus on investors who have relevant industry experience and an understanding and appreciation of the Company’s business development plans.

On 31 July 2024 the Company [announced](#) that it had entered into loan agreements to raise \$130,000 to provide short term funding to the Company. A non-related party of the Company provided \$30,000 and three Directors of the Company each provided loans of \$25,000 (\$75,000 in aggregate). The \$105,000 raised received to date has been and will be used to fund working capital expenses.

On 24 October 2024 the Company [announced](#) (**24 October Announcement**) that it had entered into an investment term sheet with Mr Rajiv Ramnarayan (**Investment Term Sheet**) pursuant to which Mr Ramnarayan will provide the Company with \$100,000 in two tranches of \$50,000. The first tranche of \$50,000 was due 25 October 2024 and has been paid. The second tranche of \$50,000 is due on 25 November 2024. The funds received and to be received from Mr Ramnarayan will be used for working capital purposes and for the development of the Indonesian-based seaweed project (see below).

The Company is continuing to engage deeply with prospective investors.

BP8 ended the quarter with cash of approximately **\$0.113** million (**\$0.134** million at 30 June 2024).

Payments of **\$9,000** were made during the quarter to related parties and their associates as remuneration. Details of these payments are included in items 6 of the Appendix 4C.

### Corporate activities

Throughout the September Quarter the Company continued to focus on business development opportunities to grow its seaweed and bird’s nest businesses. In particular, the Company has been sourcing and conducting due diligence on business development opportunities regarding:

- New sites for the cultivation of seaweed;
- Potential third-party seaweed growers for the supply of seaweed; and
- Potential third-party bird’s nest suppliers for the supply of raw and processed bird’s nest produce.

## Seaweed

Also in the 24 October Announcement, the Company announced that it had entered into an agreement with joint venture partners for the acquisition of assets and the joint development of an Indonesian-based seaweed business which, in collaboration with the joint venture partners, will enable the Company to both cultivate and harvest seaweed and to acquire seaweed from third party sellers:

- for sale as raw seaweed (such as sea grapes) into ASEAN food markets;
- for the production of bio stimulant seaweed products for sale in the Indian market;
- for the extraction of nutraceuticals for infusion in food, health and cosmetic products;
- to enable the conduct of R&D on the extraction of minerals, nano-minerals and chemicals for use in the battery and energy industries; and
- to enable the conduct of R&D on the production and extraction of biohydrogen and other biogases.

## Bird's Nest

As previously announced, the Board continues to recognise that the Company's ability to secure the supply of quality bird's products at competitive prices underpins its goal of growing its bird's nest sales numbers. A principal focus of the Company's business development strategy is to enter into additional supply agreements with one or more major suppliers of bird's nest products. The Company will provide the market with additional updates regarding its bird's nest business development activities.

- END -

Authorised for lodgement by the Board of the Company

For further information, please visit our website at [www.bp8global.com](http://www.bp8global.com) or contact:

Mr Paul Stephenson  
BPH Global Limited  
Chairman  
E: [pauls@bp8global.com](mailto:pauls@bp8global.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

BPH GLOBAL LIMITED

**ABN**

57 009 104 330

**Quarter ended ("current quarter")**

30 September 2024

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (..03..months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	52	52
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(16)	(16)
(c) advertising and marketing	-	-
(d) leased assets	(8)	(8)
(e) staff costs	(16)	(16)
(f) administration and corporate costs	(136)	(136)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(124)</b>	<b>(124)</b>

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (..03..months) \$A'000
<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses (Net)	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	-	-
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	105	105
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>105</b>	<b>105</b>

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (..03..months) \$A'000
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	134	134
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(124)	(124)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	105	105
4.5	Effect of movement in exchange rates on cash held	(2)	(2)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>113</b>	<b>113</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	106	133
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details): Cash	7	1
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>113</b>	<b>134</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	9
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. <b>Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	105	105
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-
7.5 <b>Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
Unsecured Convertible Loan Maturity: 9 February 2025, Interest: 12% per annum, Convertible into shares at \$0.003 per share, with a free attaching option for every 2 shares issued. The options are exercisable at \$0.006 per option with expiry of 3 years from date of issue.		

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(124)
8.2 Cash and cash equivalents at quarter end (item 4.6)	113
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	113
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	(0.91)
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: Yes	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: Yes. The Company is planning further placement to raise cash to fund the operations.	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: Yes. Placement is being planned to raise cash to fund the operations.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....31 October 2024.....

Authorised by: .....The Board of Directors.....  
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only